At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed adenocarcinoma of the breast
- ✓Stage IV measurable disease
- ✓Disease progression after 1-2 prior chemotherapy regimens for metastatic disease
- ✓Hormone-sensitive tumors must have received prior hormonal therapy
- ✕No clinical evidence of or known brain or CNS disease
- ✕No prior capecitabine or fluorouracil for metastatic breast cancer
- ✕No other malignancy within the past 5 years except adequately treated skin cancer or cervical carcinoma in situ
- ✕No history of severe hypersensitivity reaction to imatinib mesylate, capecitabine, or fluorouracil
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial Of Imatinib Mesylate (Gleevec®) (NSC-716051) In Combination With Capecitabine (Xeloda®) (NSC-712807) In Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Capecitabine and Imatinib mesylate for Breast Cancer. Completed, enrolled 27 participants.
Detailed Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining imatinib mesylate with capecitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with capecitabine works in treating women with progressive stage IV breast cancer.
Study Details
Timeline
Interventions
1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle
400 mg by mouth daily